References
Key articles
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Mycobacterium tuberculosis. 2024 [internet publication].Full text
World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Jun 2022 [internet publication].Full text
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416.Full text Abstract
Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb 1;50(3):291-322.Full text Abstract
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.Full text Abstract
Reference articles
1. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Mycobacterium tuberculosis. 2024 [internet publication].Full text
2. Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993 Nov;148(5):1292-7. Abstract
3. Breen RA, Smith CJ, Cropley I, et al. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS. 2005 Jul 22;19(11):1201-6. Abstract
4. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014 Jul 19;384(9939):241-8. Abstract
5. Croxford S, Miller RF, Post FA, et al. Cause of death among HIV patients in London in 2016. HIV Med. 2019 Oct;20(9):628-33.Full text Abstract
6. Hanna DB, Gupta LS, Jones LE, et al. AIDS-defining opportunistic illnesses in the HAART era in New York City. AIDS Care. 2007 Feb;19(2):264-72. Abstract
7. Bonnet F, Lewden C, May T, et al. Mortalite 2000 Study Group. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37(6-7):482-7. Abstract
8. Lewden C, Salmon D, Morlat P, et al. Mortality 2000 study group. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005 Feb;34(1):121-30.Full text Abstract
9. UNAIDS. Global HIV & AIDS statistics — fact sheet. 2023 [internet publication].Full text
10. GBD 2019 Tuberculosis Collaborators. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022 Feb;22(2):222-41.Full text Abstract
11. Patel PK, Erlandsen JE, Kirkpatrick WR, et al. The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. AIDS Res Treat. 2012;2012:262471.Full text Abstract
12. Edwards D, Kirkpatrick CH. The immunology of mycobacterial diseases. Am Rev Respir Dis. 1986 Nov;134(5):1062-71. Abstract
13. Cayrou C, Turenne C, Behr MA, et al. Genotyping of Mycobacterium avium complex organisms using multispacer sequence typing. Microbiology (Reading). 2010 Mar;156(pt 3):687-94.Full text Abstract
14. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis. 2004 Sep;4(9):557-65. Abstract
15. Drew WL. Diagnosis of cytomegalovirus infection. Rev Infect Dis. 1988 Jul-Aug;10(suppl 3):S468-76. Abstract
16. Staras SA, Flanders WD, Dollard SC, et al. Cytomegalovirus seroprevalence and childhood sources of infection: a population-based study among pre-adolescents in the United States. J Clin Virol. 2008 Nov;43(3):266-71. Abstract
17. Handsfield HH, Chandler SH, Caine VA, et al. Cytomegalovirus infection in sex partners: evidence for sexual transmission. J Infect Dis. 1985 Feb;151(2):344-8. Abstract
18. Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002 Sep;8(9):891-6.Full text Abstract
19. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004 Jun 12;363(9425):1965-76. Abstract
20. Luft BJ, Chua A. Central nervous system toxoplasmosis in HIV pathogenesis, diagnosis, and therapy. Curr Infect Dis Rep. 2000 Aug;2(4):358-62. Abstract
21. Nosanchuk JD, Shoham S, Fries BC, et al. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 2000 Feb 1;132(3):205-8. Abstract
22. Sorvillo F, Beall G, Turner PA, et al. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS. 1997 Apr;11(5):673-9. Abstract
23. Reyna-Rodríguez IL, Ocampo-Candiani J, Chavez-Alvarez S. Primary cutaneous coccidioidomycosis: an update. Am J Clin Dermatol. 2020 Oct;21(5):681-96. Abstract
24. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis. 1996 Jul-Sep;2(3):192-9. Abstract
25. Anstead GM, Graybill JR. Coccidioidomycosis. Infect Dis Clin North Am. 2006 Sep;20(3):621-43. Abstract
26. Hellerstein MK, McCune JM. T cell turnover in HIV-1 disease. Immunity. 1997 Nov;7(5):583-9.Full text Abstract
27. Liu X, Liu H, Guo Z, et al. Association of asymptomatic oral candidal carriage, oral candidiasis and CD4 lymphocyte count in HIV-positive patients in China. Oral Dis. 2006 Jan;12(1):41-4. Abstract
28. Gottfredsson M, Cox GM, Indridason OS, et al. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis. 1999 Aug;180(2):534-7.Full text Abstract
29. Yeh CK, Fox PC, Ship JA, et al. Oral defense mechanisms are impaired early in HIV-1 infected patients. J Acquir Immune Defic Syndr. 1988;1(4):361-6. Abstract
30. Meltzer MS, Skillman DR, Gomatos PJ, et al. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol. 1990;8:169-94. Abstract
31. Gray JR, Rabeneck L. Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol. 1989 Dec;84(12):1521-4. Abstract
32. Stacey AR. Isolation of Mycobacterium avium-intracellulare-scrofulaceum complex from faeces of patients with AIDS. Br Med J (Clin Res Ed). 1986 Nov 8;293(6556):1194.Full text Abstract
33. Gerna G, Parea M, Percivalle E, et al. Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection. AIDS. 1990 Oct;4(10):1027-31. Abstract
34. Gigliotti F, Wright TW. Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev Mol Med. 2005 Nov 14;7(26):1-16. Abstract
35. Subauste CS, Remington JS. Immunity to Toxoplasma gondii. Curr Opin Immunol. 1993 Aug;5(4):532-7. Abstract
36. Hunter CA, Lieberman LA, Mason N, et al. Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma. Immunol Res. 2003;27(2-3):331-40. Abstract
37. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016 Mar;30(1):179-206. Abstract
38. Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Med Mycol. 2019 Feb 1;57(2):133-50.Full text Abstract
39. Dionne SO, Podany AB, Ruiz YW, et al. Spherules derived from Coccidioides posadasii promote human dendritic cell maturation and activation. Infect Immun. 2006 Apr;74(4):2415-22.Full text Abstract
40. Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med. 1993 Mar;94(3):235-40. Abstract
41. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005 Jan 15;191(2):150-8.Full text Abstract
42. Havlir DV, Getahun H, Sanne I, et al. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23;300(4):423-30. Abstract
43. Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. PeerJ. 2017;5:e4165.Full text Abstract
44. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161-5. Abstract
45. Grant IH, Gold JW, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS. 1990 Jun;4(6):519-21. Abstract
46. Israelski DM, Chmiel JS, Poggensee L, et al. Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr (1988). 1993 Apr;6(4):414-8. Abstract
47. Mathews WC, Fullerton SC. Use of a clinical laboratory database to estimate Toxoplasma seroprevalence among human immunodeficiency virus-infected patients. Overcoming bias in secondary analysis of clinical records. Arch Pathol Lab Med. 1994 Aug;118(8):807-10. Abstract
48. Jones JL, Kruszon-Moran D, Sanders-Lewis K, et al. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg. 2007 Sep;77(3):405-10. Abstract
49. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995 Aug;21(suppl 1):S103-7. Abstract
50. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991 Nov-Dec;13(6):1163-9. Abstract
51. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. 1992 Jun;165(6):1082-5. Abstract
52. Sax PE. Opportunistic infections in HIV disease: down but not out. Infect Dis Clin North Am. 2001 Jun;15(2):433-55. Abstract
53. Remis RS, Liu J, Loutfy MR, et al. Prevalence of sexually transmitted viral and bacterial infections in HIV-positive and HIV-negative men who have sex with men in Toronto. PLoS One. 2016;11(7):e0158090.Full text Abstract
54. Lin RY, Goodhart PT. Population characteristics of tuberculosis in an HIV/AIDS registry from an East Harlem Hospital. N Y State J Med. 1991 Jun;91(6):239-42. Abstract
55. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 1;50(11):1439-47.Full text Abstract
56. Jackson JB, Erice A, Englund JA, et al. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion. 1988 Mar-Apr;28(2):187-9. Abstract
57. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008 Feb 1;177(3):348-55.Full text Abstract
58. Carr A, Tindall B, Penny R, et al. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS. 1992 Feb;6(2):165-71. Abstract
59. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim/sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995 May 15;122(10):755-61. Abstract
60. Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis. 2001 Dec 1;33(11):1901-9.Full text Abstract
61. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med. 2000 May 11;342(19):1416-29. Abstract
62. Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet. 2000 Jun 24;355(9222):2217-8. Abstract
63. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One. 2008 Jun 18;3(6):e2489.Full text Abstract
64. World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: tests for TB infection.Sep 2022 [internet publication].Full text
65. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11.Full text Abstract
66. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Mar 2020 [internet publication].Full text
67. Nolt D, Starke JR. Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics. 2021 Dec 1;148(6):e2021054663.Full text Abstract
68. Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-6.Full text Abstract
69. Ronald LA, FitzGerald JM, Bartlett-Esquilant G, et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. Eur Respir J. 2020 Mar;55(3):1902048.Full text Abstract
70. World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Jun 2022 [internet publication].Full text
71. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Aug 1;111(3):223-31. Abstract
72. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):75-80. Abstract
73. Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuber Lung Dis. 1995 Dec;76(6):518-21. Abstract
74. Pepper T, Joseph P, Mwenya C, et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis. 2008 Apr;12(4):397-403. Abstract
75. Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology. 1994 Oct;193(1):115-9. Abstract
76. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.Full text Abstract
77. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection 2021 update. Jul 2021 [internet publication].Full text
78. Zifodya JS, Kreniske JS, Schiller I, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021 Feb 22;2:CD009593.Full text Abstract
79. Shapiro AE, Ross JM, Yao M, et al. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD013694.Full text Abstract
80. Pillay S, Steingart KR, Davies GR, et al. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841.Full text Abstract
81. Haraka F, Kakolwa M, Schumacher SG, et al. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. Cochrane Database Syst Rev. 2021 May 6;5(5):CD012972.Full text Abstract
82. Kohli M, Schiller I, Dendukuri N, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD012768.Full text Abstract
83. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):7-10.Full text Abstract
84. Bjerrum S, Schiller I, Dendukuri N, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev. 2019 Oct 21;(10):CD011420.Full text Abstract
85. Nathavitharana RR, Lederer P, Chaplin M, et al. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev. 2021 Aug 20;(8):CD014641.Full text Abstract
86. Aljohaney A, Amjadi K, Alvarez GG. A systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients. Clin Dev Immunol. 2012;2012:842045.Full text Abstract
87. Baba K, Hoosen AA, Langeland N, et al. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One. 2008 Jul 30;3(7):e2788.Full text Abstract
88. Long R, Maycher B, Scalcini M, et al. The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest. 1991 Jan;99(1):123-7. Abstract
89. Torok ME, Chau TT, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS One. 2008 Mar 19;3(3):e1772.Full text Abstract
90. Aaron L, Saadoun D, Calatroni, I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect. 2004 May;10(5):388-98.Full text Abstract
91. Shafer RW, Kim DS, Weiss JP, et al. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore). 1991 Nov;70(6):384-97. Abstract
92. Mistry BJ, Kala UK. Palatial erosion caused by Mycobacterium Avium complex in a human immunodeficiency virus infected child. Pediatr Infect Dis J. 2007 Jun;26(6):546-8. Abstract
93. Blumenthal DR, Zucker JR, Hawkins CC. Mycobacterium avium complex-induced septic arthritis and osteomyelitis in a patient with the acquired immunodeficiency syndrome. Arthritis Rheum. 1990 May;33(5):757-8. Abstract
94. Cappell MS, Gupta A. Gastrointestinal hemorrhage due to gastrointestinal Mycobacterium avium intracellulare or esophageal candidiasis in patients with the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992 Feb;87(2):224-9. Abstract
95. Stone BL, Cohn DL, Kane MS, et al. Utility of paired blood cultures and smears in diagnosis of disseminated Mycobacterium avium complex infections in AIDS patients. J Clin Microbiol. 1994 Mar;32(3):841-2.Full text Abstract
96. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416.Full text Abstract
97. Ellison E, Lapuerta P, Martin SE. Fine needle aspiration diagnosis of mycobacterial lymphadenitis. Sensitivity and predictive value in the United States. Acta Cytol. 1999 Mar-Apr;43(2):153-7. Abstract
98. Koh DM, Burn PR, Mathews G, et al. Abdominal computed tomographic findings of Mycobacterium tuberculosis and Mycobacterium avium intracellulare infection in HIV seropositive patients. Can Assoc Radiol J. 2003 Feb;54(1):45-50. Abstract
99. Pantongrag-Brown L, Krebs TL, Daly BD, et al. Frequency of abdominal CT findings in AIDS patients with M. avium complex bacteraemia. Clin Radiol. 1998 Nov;53(11):816-9. Abstract
100. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May;100(5):663-71. Abstract
101. Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018;96(1):52-65.Full text Abstract
102. Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for Pneumocystis carinii pneumonia. Semin Respir Infect. 1997 Jun;12(2):70-8. Abstract
103. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis. 1988 Apr;137(4):796-800. Abstract
104. Miller RF, Huang L, Walzer PD. Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med. 2013 Jun;34(2):229-41.Full text Abstract
105. Smith DE, McLuckie A, Wyatt J, et al. Severe exercise hypoxaemia with normal or near normal x-rays: a feature of Pneumocystis carinii infection. Lancet. 1988 Nov 5;2(8619):1049-51. Abstract
106. DeLorenzo LJ, Huang CT, Maguire GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987 Mar;91(3):323-7. Abstract
107. Abd AG, Nierman DM, Ilowite JS, et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest. 1988 Aug;94(2):329-31. Abstract
108. Hidalgo A, Falco V, Mauleon S, et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non-Pneumocystis carinii pneumonia in AIDS patients. Eur Radiol. 2003 May;13(5):1179-84. Abstract
109. Luft BJ, Brooks RG, Conley FK, et al. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA. 1984 Aug 17;252(7):913-7. Abstract
110. Rabaud C, May T, Lucet JC, et al. Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey. Clin Infect Dis. 1996 Dec;23(6):1249-54. Abstract
111. Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology. 2004 Apr;111(4):716-25. Abstract
112. Smego RA Jr, Orlovic D, Wadula, J. An algorithmic approach to intracranial mass lesions in HIV/AIDS. Int J STD AIDS. 2006 Apr;17(4):271-6. Abstract
113. Mesquita RT, Ziegler ÂP, Hiramoto RM, et al. Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients. J Med Microbiol. 2010 Jun;59(pt 6):641-7.Full text Abstract
114. Levy RM, Mills CM, Posin JP, et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr. 1990;3(5):461-71. Abstract
115. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993 Sep 30;329(14):995-1000.Full text Abstract
116. Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med. 1998 Aug;39(8):1366-9.Full text Abstract
117. Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics. 2005 Sep-Oct;25(5):1357-68. Abstract
118. Rosenfeld SS, Hoffman JM, Coleman RE, et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med. 1992 Apr;33(4):532-6. Abstract
119. Giancola ML, Rizzi EB, Schiavo R, et al. Reduced value of thallium-201 single-photon emission computed tomography in the management of HIV-related focal brain lesions in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2004 Jun;20(6):584-8. Abstract
120. Antinori A, Ammassari A, Luzzati R, et al. Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & Tumori. Neurology. 2000 Feb 22;54(4):993-7. Abstract
121. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-83.Full text Abstract
122. Meiselman MS, Cello JP, Margaretten W. Cytomegalovirus colitis. Report of the clinical, endoscopic, and pathologic findings in two patients with the acquired immune deficiency syndrome. Gastroenterology. 1985 Jan;88(1 Pt 1):171-5. Abstract
123. Anders HJ, Goebel FD. Cytomegalovirus polyradiculopathy in patients with AIDS. Clin Infect Dis. 1998 Aug;27(2):345-52. Abstract
124. Brantsaeter AB, Holberg-Petersen M, Jeansson S, et al. CMV quantitative PCR in the diagnosis of CMV disease in patients with HIV-infection - a retrospective autopsy based study. BMC Infect Dis. 2007 Nov 6;7:127.Full text Abstract
125. Jabs DA, Gilpin AM, Min YI, et al. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS. 2002 Apr 12;16(6):877-87.Full text Abstract
126. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004 May 29;363(9423):1764-7. Abstract
127. Darras-Joly C, Chevret S, Wolff M, et al. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin Infect Dis. 1996 Aug;23(2):369-76. Abstract
128. Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014 Jan;20(1):45-53.Full text Abstract
129. Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994 Jul;32(7):1680-4.Full text Abstract
130. Asawavichienjinda T, Sitthi-Amorn C, Tanyanont V. Serum cyrptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis. J Med Assoc Thai. 1999 Jan;82(1):65-71. Abstract
131. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol. 2016 Sep;54(9):2251-61.Full text Abstract
132. Bianchi M, Robles AM, Vitale R, et al. The usefulness of blood culture in diagnosing HIV-related systemic mycoses: evaluation of a manual lysis centrifugation method. Med Mycol. 2000 Feb;38(1):77-80.Full text Abstract
133. Millsop JW, Fazel N. Oral candidiasis. Clin Dermatol. 2016 Jul-Aug;34(4):487-94. Abstract
134. Underwood JA, Williams JW, Keate RF. Clinical findings and risk factors for Candida esophagitis in outpatients. Dis Esophagus. 2003;16(2):66-9.Full text Abstract
135. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis. 1995 Aug;21(suppl 1):S99-102. Abstract
136. Lehner T. Classification and clinicopathological features of Candida infections in the mouth. In: Hurley R, Winner HI, eds. Symposium on Candida infections. Edinburgh and London: E. & S. Livingstone;1996:119.
137. Thom K, Forrest G. Gastrointestinal infections in immunocompromised hosts. Curr Opin Gastroenterol. 2006 Jan;22(1):18-23. Abstract
138. Nokta M. Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep. 2008 Feb;5(1):5-12. Abstract
139. Valdivia L, Nix D, Wright M, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis. 2006 Jun;12(6):958-62.Full text Abstract
140. Hernández JL, Echevarría S, García-Valtuille A, et al. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis. 1997 Aug;16(8):592-4. Abstract
141. Saubolle MA, Wojack BR, Wertheimer AM, et al. Multicenter clinical validation of a cartridge-based real-time PCR system for detection of Coccidioides spp. in lower respiratory specimens. J Clin Microbiol. 2018 Feb;56(2):e01277-17.Full text Abstract
142. Stevens DA, Clemons KV, Levine HB, et al. Expert opinion: what to do when there is Coccidioides exposure in a laboratory. Clin Infect Dis. 2009 Sep 15;49(6):919-23.Full text Abstract
143. Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev. 1990 Jul;3(3):247-68.Full text Abstract
144. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999 Feb 4;340(5):367-73. Abstract
145. Armstrong WS, Katz JT, Kazanjian PH. Human immunodeficiency virus-associated fever of unknown origin: a study of 70 patients in the United States and review. Clin Infect Dis. 1999 Feb;28(2):341-5.Full text Abstract
146. Havlik JA Jr, Horsburgh CR Jr, Metchock B, et al. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis. 1992 Mar;165(3):577-80. Abstract
147. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007 Feb;13(1):1-7. Abstract
148. Mayo J, Collazos J, Martinez E. Fever of unknown origin in the HIV-infected patient: new scenario for an old problem. Scand J Infect Dis. 1997;29(4):327-36. Abstract
149. Navia BA, Petito CK, Gold JW, et al. Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients. Ann Neurol. 1986 Mar;19(3):224-38. Abstract
150. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 2005 Apr 18;72:99-118.Full text Abstract
151. Donald PR, Schoeman JF. Tuberculous meningitis. N Engl J Med. 2004 Oct 21;351(17):1719-20. Abstract
152. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis. 1995 Apr;20(4):747-54. Abstract
153. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998 Jan 24;351(9098):252-5. Abstract
154. Jabs DA. AIDS and ophthalmology, 2008. Arch Ophthalmol. 2008 Aug;126(8):1143-6. Abstract
155. Patel NS, Vavvas DG. Ocular toxoplasmosis: a review of current literature. Int Ophthalmol Clin. 2022 Apr 1;62(2):231-50. Abstract
156. Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore). 1993 Jul;72(4):207-24. Abstract
157. Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French national survey. Medicine (Baltimore). 1994 Nov;73(6):306-14. Abstract
158. Stover DE, Greeno RA, Gagliardi AJ. The use of a simple exercise test for the diagnosis of Pneumocystis carinii pneumonia in patients with AIDS. Am Rev Respir Dis. 1989 Jun;139(6):1343-6. Abstract
159. Hodge WG, Boivin JF, Shapiro SH, et al. Clinical risk factors for cytomegalovirus retinitis in patients with AIDS. Ophthalmology. 2004 Jul;111(7):1326-33. Abstract
160. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000 Jan;30(1):47-54.Full text Abstract
161. Laborada J, Cohen PR. Tuberculosis-associated erythema nodosum. Cureus. 2021 Dec;13(12):e20184.Full text Abstract
162. Rizvi Z, Iqbal T, Javed A, et al. Erythema nodosum: a consequence of tuberculosis. Cureus. 2019 May 23;11(5):e4724.Full text Abstract
163. Gushiken AC, Saharia KK, Baddley JW. Cryptococcosis. Infect Dis Clin North Am. 2021 Jun;35(2):493-514. Abstract
164. Garcia Garcia SC, Salas Alanis JC, Flores MG, et al. Coccidioidomycosis and the skin: a comprehensive review. An Bras Dermatol. 2015 Sep-Oct;90(5):610-9.Full text Abstract
165. Yagupsky P, Menegus MA. Cumulative positivity rates of multiple blood cultures for Mycobacterium avium-intracellulare and Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1990 Sep;114(9):923-5. Abstract
166. Colombo FA, Vidal JE, Penalva de Oliveira AC, et al. Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples. J Clin Microbiol. 2005 Oct;43(10):5044-7.Full text Abstract
167. Letang E, Müller MC, Ntamatungiro AJ, et al. Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis. 2015 Apr;2(2):ofv046.Full text Abstract
168. Gascon P, Sathe SS, Rameshwar P. Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex. Am J Med. 1993 Jan;94(1):41-8. Abstract
169. Horsburgh CR Jr, Metchock B, Gordon SM, et al. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis. 1994 Sep;170(3):573-7. Abstract
170. Graviss EA, Vanden Heuvel EA, Lacke CE, et al. Clinical prediction model for differentiation of disseminated Histoplasma capsulatum and Mycobacterium avium complex infections in febrile patients with AIDS. J Acquir Immune Defic Syndr. 2000 May 1;24(1):30-6. Abstract
171. Chang YG, Chen PJ, Hung CC, et al. Opportunistic hepatic infections in AIDS patients with fever of unknown origin. J Formos Med Assoc. 1999 Jan;98(1):5-10. Abstract
172. Kuhlman JE. Pneumocystic infections: the radiologist's perspective. Radiology. 1996 Mar;198(3):623-35. Abstract
173. Salomon N, Perlman DC. Cytomegalovirus pneumonia. Semin Respir Infect. 1999 Dec;14(4):353-8. Abstract
174. Olatinwo TF, Herbowy MT, Hewitt RG. Toxoplasmic encephalitis and primary lymphoma of the brain-the shift in epidemiology: a case series and review of the literature. AIDS Read. 2001 Sep;11(9):444-9. Abstract
175. Coleman DL, Dodek PM, Luce JM, et al. Diagnostic utility of fiberoptic bronchoscopy in patients with Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome. Am Rev Respir Dis. 1983 Nov;128(5):795-9. Abstract
176. Aderaye G, Woldeamanuel Y, Asrat D, et al. Evaluation of Toluidine Blue O staining for the diagnosis of Pneumocystis jiroveci in expectorated sputum sample and bronchoalveolar lavage from HIV-infected patients in a tertiary care referral center in Ethiopia. Infection. 2008 Jun;36(3):237-43. Abstract
177. Stover DE, White DA, Romano PA, et al. Diagnosis of pulmonary disease in acquired immune deficiency syndrome (AIDS). Role of bronchoscopy and bronchoalveolar lavage. Am Rev Respir Dis. 1984 Oct;130(4):659-62. Abstract
178. Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1405-12. Abstract
179. Dupon M, Cazenave J, Pellegrin JL, et al. Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients. J Clin Microbiol. 1995 Sep;33(9):2421-6.Full text Abstract
180. Akpek G, Lee SM, Gagnon DR, et al. Bone marrow aspiration, biopsy, and culture in the evaluation of HIV-infected patients for invasive mycobacteria and histoplasma infections. Am J Hematol. 2001 Jun;67(2):100-6.Full text Abstract
181. Tarantino L, Giorgio A, de Stefano G, et al. Disseminated mycobacterial infection in AIDS patients: abdominal US features and value of fine-needle aspiration biopsy of lymph nodes and spleen. Abdom Imaging. 2003 Sep-Oct;28(5):602-8. Abstract
182. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol. 2006 Sep;37(1):1-9. Abstract
183. Fee MJ, Oo MM, Gabayan AE, et al. Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1995 Apr;20(4):938-44. Abstract
184. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997 Oct;169(4):967-75.Full text Abstract
185. McGuinness G. Changing trends in the pulmonary manifestations of AIDS. Radiol Clin North Am. 1997 Sep;35(5):1029-82. Abstract
186. Rene E, Marche C, Chevalier T, et al. Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. Dig Dis Sci. 1988 Jun;33(6):741-50. Abstract
187. Wilcox CM, Schwartz DA. Endoscopic-pathologic correlates of Candida esophagitis in acquired immunodeficiency syndrome. Dig Dis Sci. 1996 Jul;41(7):1337-45. Abstract
188. Centers for Disease Control and Prevention. Tuberculosis (TB) (Mycobacterium tuberculosis) 2009 case definition. Apr 2021 [internet publication].Full text
189. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. Jan 2020 [internet publication].Full text
190. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19.Full text Abstract
191. World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. Mar 2021 [internet publication].Full text
192. U.S. Preventive Services Task Force. Latent tuberculosis infection in adults: screening. May 2023 [internet publication].Full text
193. Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016 Sep 15;63(6):e112-46.Full text Abstract
194. Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. Department of Health and Human Services. Sep 2023 [internet publication].Full text
195. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10.Full text Abstract
196. Zolopa A, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575.Full text Abstract
197. El-Sadr WMG, Grund B, Neuhaus J, et al; SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008 Sep 2;149(5):289-99. Abstract
198. British HIV Association. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2023 interim update). 2023 [internet publication].Full text
199. Munseri PJ, Talbot EA, Mtei L, et al. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008 Sep;12(9):1037-41. Abstract
200. Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):313-316.Full text Abstract
201. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195.Full text Abstract
202. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].Full text
203. Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-18.Full text Abstract
204. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication].Full text
205. Telzak EE, Chirgwin KD, Nelson ET, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Int J Tuberc Lung Dis. 1999 Apr;3(4):337-43. Abstract
206. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD005159. Abstract
207. British HIV Association. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). Aug 2016 [internet publication].Full text
208. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. Abstract
209. Gardner EM, Burman WJ, DeGroote MA, et al. Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients. Clin Infect Dis. 2005 Oct 1;41(7):1041-4.Full text Abstract
210. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017 Nov;72(suppl 2):ii1-64.Full text Abstract
211. Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003 Nov 1;37(9):1234-43.Full text Abstract
212. Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med. 1992 Mar 15;116(6):466-72. Abstract
213. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med. 2000 Apr 13;342(15):1085-92.Full text Abstract
214. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996 May 1;124(9):792-802. Abstract
215. Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 2003 Jan 3;17(1):73-80.Full text Abstract
216. Montaner JS, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Jul 1;113(1):14-20. Abstract
217. Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008 May 1;48(1):63-7.Full text Abstract
218. National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990 Nov 22;323(21):1500-4.Full text Abstract
219. Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001 May 1;183(9):1409-12.Full text Abstract
220. Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome. J Infect Dis. 1996 May;173(5):1294-5. Abstract
221. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1998 Jun;42(6):1346-9.Full text Abstract
222. Hernandez AV, Thota P, Pellegrino D, et al. A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med. 2017 Feb;18(2):115-24.Full text Abstract
223. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb 1;50(3):291-322.Full text Abstract
224. van der Horst C, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997 Jul 3;337(1):15-21.Full text Abstract
225. European Medicines Agency. Flucytosine: updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. Jun 2020 [internet publication].Full text
226. Medicines and Healthcare products Regulatory Agency. Flucytosine (Ancotil): new contraindication in patients with DPD deficiency. Oct 2020 [internet publication].Full text
227. Larsen RA. Editorial response: a comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999 Feb;28(2):297-8.Full text Abstract
228. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis. 2003 May 15;36(10):1329-31.Full text Abstract
229. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993 Dec;168(6):1506-9. Abstract
230. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.Full text Abstract
231. Hegener P, Troke PF, Fätkenheuer G, et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS. 1998 Nov 12;12(16):2227-8. Abstract
232. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000 Nov 7;133(9):676-86. Abstract
233. Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011 Dec;53(11):1060-6.Full text Abstract
234. Tucker RM, Denning DW, Dupont B, et al. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990 Jan 15;112(2):108-12. Abstract
235. Hamza OJ, Matee MI, Bruggemann RJ, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis. 2008 Nov 15;47(10):1270-6.Full text Abstract
236. Wang F, Langley R, Gulten G, et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.Full text Abstract
237. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006 Oct 15;43(8):1060-8.Full text Abstract
238. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012 Jun 1;26(9):1105-13.Full text Abstract
239. Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother. 2019 Mar;63(3):e02337-18.Full text Abstract
240. Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011.Full text Abstract
241. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel. JAMA. 2023;329(1):63-84.Full text
242. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. Jun 2013 [internet publication].Full text
243. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020 Jul 7;56(1):2000535.Full text Abstract
244. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - second edition. Jun 2016 [internet publication].Full text
245. European AIDS Clinical Society. Guidelines version 12.0. Oct 2023 [internet publication].Full text
246. Raviglione MC. Facing extensively drug-resistant tuberculosis-a hope and a challenge. N Engl J Med. 2008 Aug 7;359(6):636-8.Full text Abstract
247. Driver CR, Munsiff SS, Li J, et al. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001 Nov 15;33(10):1762-9.Full text Abstract
248. Corti M, Palmero D. Mycobacterium avium complex infection in HIV/AIDS patients. Expert Rev Anti Infect Ther. 2008 Jun;6(3):351-63. Abstract
249. Vidal JE, Hernandez AV, de Oliveira AC, et al. Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS. 2005 Oct;19(10):626-34. Abstract
250. Hoffmann C, Ernst M, Meyer P, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect. 2007 May;13(5):510-5.Full text Abstract
251. Signorini L, Gulletta M, Coppini D, et al. Fatal disseminated toxoplasmosis during primary HIV infection. Curr HIV Res. 2007 Mar;5(2):273-4. Abstract
252. Person AK, Crabtree-Ramirez B, Kim A, et al. Cryptococcal meningitis and clinical outcomes in persons with human immunodeficiency virus: a global view. Clin Infect Dis. 2023 Jun 16;76(12):2116-25. Abstract
253. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008 Jun 1;46(11):1694-701.Full text Abstract
254. Kedhar DR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes. 2007 Dec;14(3):66-71. Abstract
255. Launay O, Lortholary O, Bouges-Michel C, et al. Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis. 1998 May;26(5):1134-41. Abstract
256. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005 Nov 15;41(10):1483-97.Full text Abstract
257. Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007 May 8;4:9.Full text Abstract
258. Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Apr;10(4):251-61.Full text Abstract
259. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One. 2010 Jul 1;5(7):e11416.Full text Abstract
260. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1049-1052.Full text Abstract
261. Accorinti M, Pirraglia MP, Corradi R, et al. Changing patterns of ocular manifestations in HIV seropositive patients treated with HAART. Eur J Ophthalmol. 2006 Sep-Oct;16(5):728-32. Abstract
262. Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006 Aug;113(8):1432-40. Abstract
263. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004 Dec;111(12):2224-31. Abstract
264. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004 Dec;111(12):2232-9. Abstract
265. National Tuberculosis Controllers Association, Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005 Dec 16;54(RR-15):1-47.Full text Abstract
266. Miro JM, Lopez JC, Podzamczer D, et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006 Jul 1;43(1):79-89.Full text Abstract
267. Walmsley SL, Raboud J, Angel JB, et al. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials. 2006 Jan-Feb;7(1):1-9. Abstract
268. Soriano V, Dona C, Rodriguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2000 Mar 10;14(4):383-6. Abstract
Use of this content is subject to our disclaimer